Dextromethorphan attenuated inflammation and combined opioid use in humans undergoing methadone maintenance treatment

Shiou Lan Chen; Sheng Yu Lee; Pao Luh Tao; Yun Hsuan Chang; Shih Heng Chen; Chun Hsien Chu; Po See Chen; I. Hui Lee; Tzung Lieh Yeh; Yen Kuang Yang; Jau Shyong Hong; Ru Band Lu

doi:10.1007/s11481-012-9400-1

Dextromethorphan attenuated inflammation and combined opioid use in humans undergoing methadone maintenance treatment

Shiou Lan Chen, Sheng Yu Lee, Pao Luh Tao, Yun Hsuan Chang, Shih Heng Chen, Chun Hsien Chu, Po See Chen, I. Hui Lee, Tzung Lieh Yeh, Yen Kuang Yang, Jau Shyong Hong, Ru Band Lu

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Recent studies show that proinflammatory cytokines might be related to the development of opioid dependence (physiological, psychological, or both). In a double-blind, randomly stratified clinical trial investigating whether add-on dextromethorphan (60-120 mg/day) attenuated inflammation and the combined use of opioids in heroin-dependent patients undergoing methadone maintenance treatment, we evaluated whether inflammation is related to the progression of opioid dependence. All participants (107 heroin-dependent patients and 84 nondependent healthy controls) were recruited from National Cheng Kung University Hospital. Their plasma cytokine levels were measured to evaluate the effect of add-on dextromethorphan. Plasma TNF-α and IL-8 levels were significantly higher in long-term heroin-dependent patients than in healthy controls (p < 0.001). Chronic heroin-use-induced TNF-α and IL-8 levels were significantly (p < 0.05) attenuated in patients treated for 12 weeks with add-on dextromethorphan. Moreover, both tolerance to methadone and the combined use of opioids were significantly (p < 0.05) attenuated in patients taking dextromethorphan. We conclude that dextromethorphan might be a feasible adjuvant therapeutic for attenuating inflammation and inhibiting methadone tolerance and combined opioid use in heroin-dependent patients.

Original language	English
Pages (from-to)	1025-1033
Number of pages	9
Journal	Journal of Neuroimmune Pharmacology
Volume	7
Issue number	4
DOIs	https://doi.org/10.1007/s11481-012-9400-1
Publication status	Published - 2012 Dec

All Science Journal Classification (ASJC) codes

Neuroscience (miscellaneous)
Immunology and Allergy
Immunology
Pharmacology

Access to Document

10.1007/s11481-012-9400-1

Cite this

Chen, S. L., Lee, S. Y., Tao, P. L., Chang, Y. H., Chen, S. H., Chu, C. H., Chen, P. S., Lee, I. H., Yeh, T. L., Yang, Y. K., Hong, J. S., & Lu, R. B. (2012). Dextromethorphan attenuated inflammation and combined opioid use in humans undergoing methadone maintenance treatment. Journal of Neuroimmune Pharmacology, 7(4), 1025-1033. https://doi.org/10.1007/s11481-012-9400-1

@article{b765ecbf9c3a42c8b5d24c6a95aa9ec6,

title = "Dextromethorphan attenuated inflammation and combined opioid use in humans undergoing methadone maintenance treatment",

abstract = "Recent studies show that proinflammatory cytokines might be related to the development of opioid dependence (physiological, psychological, or both). In a double-blind, randomly stratified clinical trial investigating whether add-on dextromethorphan (60-120 mg/day) attenuated inflammation and the combined use of opioids in heroin-dependent patients undergoing methadone maintenance treatment, we evaluated whether inflammation is related to the progression of opioid dependence. All participants (107 heroin-dependent patients and 84 nondependent healthy controls) were recruited from National Cheng Kung University Hospital. Their plasma cytokine levels were measured to evaluate the effect of add-on dextromethorphan. Plasma TNF-α and IL-8 levels were significantly higher in long-term heroin-dependent patients than in healthy controls (p < 0.001). Chronic heroin-use-induced TNF-α and IL-8 levels were significantly (p < 0.05) attenuated in patients treated for 12 weeks with add-on dextromethorphan. Moreover, both tolerance to methadone and the combined use of opioids were significantly (p < 0.05) attenuated in patients taking dextromethorphan. We conclude that dextromethorphan might be a feasible adjuvant therapeutic for attenuating inflammation and inhibiting methadone tolerance and combined opioid use in heroin-dependent patients.",

author = "Chen, {Shiou Lan} and Lee, {Sheng Yu} and Tao, {Pao Luh} and Chang, {Yun Hsuan} and Chen, {Shih Heng} and Chu, {Chun Hsien} and Chen, {Po See} and Lee, {I. Hui} and Yeh, {Tzung Lieh} and Yang, {Yen Kuang} and Hong, {Jau Shyong} and Lu, {Ru Band}",

note = "Funding Information: Acknowledgments This study was supported in part by grant DOH98-TD-I-111-DD004 from the Taiwan Ministry of Health (to R-BL); grants NHRI-EX97-9401NP (to P-LT) and NHRI-99A1-PDCO-0809111 (to P-LT) from the Taiwan National Health Research Institutes; and a grant from the National Cheng Kung University Project to Promote Academic Excellence & Develop World Class Research Centers (to R-BL). We thank Ms. Yi-Syuan Wu and Ms. Yu-Shan Wang for their assistance in preparing this manuscript. R-B Lu had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.",

year = "2012",

month = dec,

doi = "10.1007/s11481-012-9400-1",

language = "English",

volume = "7",

pages = "1025--1033",

journal = "Journal of Neuroimmune Pharmacology",

issn = "1557-1890",

publisher = "Springer New York",

number = "4",

}

TY - JOUR

T1 - Dextromethorphan attenuated inflammation and combined opioid use in humans undergoing methadone maintenance treatment

AU - Chen, Shiou Lan

AU - Lee, Sheng Yu

AU - Tao, Pao Luh

AU - Chang, Yun Hsuan

AU - Chen, Shih Heng

AU - Chu, Chun Hsien

AU - Chen, Po See

AU - Lee, I. Hui

AU - Yeh, Tzung Lieh

AU - Yang, Yen Kuang

AU - Hong, Jau Shyong

AU - Lu, Ru Band

N1 - Funding Information: Acknowledgments This study was supported in part by grant DOH98-TD-I-111-DD004 from the Taiwan Ministry of Health (to R-BL); grants NHRI-EX97-9401NP (to P-LT) and NHRI-99A1-PDCO-0809111 (to P-LT) from the Taiwan National Health Research Institutes; and a grant from the National Cheng Kung University Project to Promote Academic Excellence & Develop World Class Research Centers (to R-BL). We thank Ms. Yi-Syuan Wu and Ms. Yu-Shan Wang for their assistance in preparing this manuscript. R-B Lu had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

PY - 2012/12

Y1 - 2012/12

N2 - Recent studies show that proinflammatory cytokines might be related to the development of opioid dependence (physiological, psychological, or both). In a double-blind, randomly stratified clinical trial investigating whether add-on dextromethorphan (60-120 mg/day) attenuated inflammation and the combined use of opioids in heroin-dependent patients undergoing methadone maintenance treatment, we evaluated whether inflammation is related to the progression of opioid dependence. All participants (107 heroin-dependent patients and 84 nondependent healthy controls) were recruited from National Cheng Kung University Hospital. Their plasma cytokine levels were measured to evaluate the effect of add-on dextromethorphan. Plasma TNF-α and IL-8 levels were significantly higher in long-term heroin-dependent patients than in healthy controls (p < 0.001). Chronic heroin-use-induced TNF-α and IL-8 levels were significantly (p < 0.05) attenuated in patients treated for 12 weeks with add-on dextromethorphan. Moreover, both tolerance to methadone and the combined use of opioids were significantly (p < 0.05) attenuated in patients taking dextromethorphan. We conclude that dextromethorphan might be a feasible adjuvant therapeutic for attenuating inflammation and inhibiting methadone tolerance and combined opioid use in heroin-dependent patients.

AB - Recent studies show that proinflammatory cytokines might be related to the development of opioid dependence (physiological, psychological, or both). In a double-blind, randomly stratified clinical trial investigating whether add-on dextromethorphan (60-120 mg/day) attenuated inflammation and the combined use of opioids in heroin-dependent patients undergoing methadone maintenance treatment, we evaluated whether inflammation is related to the progression of opioid dependence. All participants (107 heroin-dependent patients and 84 nondependent healthy controls) were recruited from National Cheng Kung University Hospital. Their plasma cytokine levels were measured to evaluate the effect of add-on dextromethorphan. Plasma TNF-α and IL-8 levels were significantly higher in long-term heroin-dependent patients than in healthy controls (p < 0.001). Chronic heroin-use-induced TNF-α and IL-8 levels were significantly (p < 0.05) attenuated in patients treated for 12 weeks with add-on dextromethorphan. Moreover, both tolerance to methadone and the combined use of opioids were significantly (p < 0.05) attenuated in patients taking dextromethorphan. We conclude that dextromethorphan might be a feasible adjuvant therapeutic for attenuating inflammation and inhibiting methadone tolerance and combined opioid use in heroin-dependent patients.

UR - http://www.scopus.com/inward/record.url?scp=84875829064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875829064&partnerID=8YFLogxK

U2 - 10.1007/s11481-012-9400-1

DO - 10.1007/s11481-012-9400-1

M3 - Article

C2 - 22990619

AN - SCOPUS:84875829064

SN - 1557-1890

VL - 7

SP - 1025

EP - 1033

JO - Journal of Neuroimmune Pharmacology

JF - Journal of Neuroimmune Pharmacology

IS - 4

ER -

Dextromethorphan attenuated inflammation and combined opioid use in humans undergoing methadone maintenance treatment

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this